Cosopt®
Dorzolamide HCL 2% / Timolol Maleate 0.5%
ophthalmic solution
Antiglaucoma
[ Carbonic Anhydrase Inhibitor, Beta Blocker]
Indication
Reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension
Mechanism of Action
Cosopt® combines dorzolamide, a carbonic anhydrase inhibitor, and timolol, a beta-blocker. Dorzolamide inhibits carbonic anhydrase in the ciliary processes, decreasing aqueous humor production. Timolol reduces aqueous formation by blocking beta2 receptors. This combination results in reduced intraocular pressure.
Available Quantities
5 ml in 10 ml bottle, 10 ml in 10 ml bottle
Dosage/Instructions
1 drop twice daily, 12 hours apart
Pregnancy & Nursing
Use cautiously during pregnancy. No adequate and well-controlled studies in pregnant women.
Pediatric Use
≥2 years
Contraindications, side effects, etc.
Contraindicated in patients with bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock, and hypersensitivity to any component. Warnings include potentiation of respiratory reactions including asthma, cardiac failure, sulfonamide hypersensitivity, obstructive pulmonary disease, increased reactivity to allergens, potentiation of muscle weakness, masking of hypoglycemic symptoms in diabetic patients, masking of thyrotoxicosis, renal and hepatic impairment, impairment of beta-adrenergically mediated reflexes during surgery, and potential for corneal endothelium damage. Adverse reactions include taste perversion, ocular burning/stinging, conjunctival hyperemia, blurred vision, superficial punctate keratitis, eye itching, and less commonly, gastrointestinal disturbances, drowsiness, confusion, and systemic effects due to beta-blockade.